{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T10:51:56Z","timestamp":1781866316701,"version":"3.54.5"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The President Foundation of Zhujiang Hospital, Southern Medical University"},{"name":"Beijing CSCO-Clinical Oncology Research Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Radiotherapy resistance remains a major obstacle in nasopharyngeal carcinoma (NPC). This study delineates the role of protein phosphatase 2 regulatory subunit B gamma (PPP2R2C) in NPC radioresistance and its underlying mechanism to identify therapeutic targets. Through integrated bioinformatic analysis, PPP2R2C was identified as a candidate radioresistance driver. In vitro and in vivo functional assays demonstrated that PPP2R2C depletion significantly impaired NPC cell proliferation, migration, and radioresistance, while its overexpression enhanced these phenotypes. Mechanistic investigations revealed PPP2R2C inhibits radiation-induced ferroptosis, evidenced by transmission electron microscopy (TEM), lipid reactive oxygen species (ROS) quantification, malondialdehyde (MDA) assays, and immunoblotting of glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11). Crucially, immunoprecipitation-mass spectrometry (IP-MS), co-immunoprecipitation (Co-IP), and immunofluorescence (IF) confirmed PPP2R2C physically interacts with RPS27L. Further analysis via qPCR, Western blotting, cycloheximide chase, and proteasome inhibition showed PPP2R2C stabilizes RPS27L protein by blocking proteasomal degradation. RPS27L knockdown reversed PPP2R2C-mediated radioresistance and ferroptosis suppression. Clinically, high PPP2R2C expression correlated with poor patient survival. These findings establish that PPP2R2C promotes NPC radioresistance by stabilizing RPS27L to inhibit ferroptosis, positioning the PPP2R2C\u2013RPS27L axis as a novel prognostic biomarker and therapeutic target for overcoming radioresistance.<\/jats:p>","DOI":"10.1038\/s41419-026-08732-y","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:24:08Z","timestamp":1778498648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PPP2R2C confers radioresistance in nasopharyngeal carcinoma by suppressing ferroptosis via RPS27L stabilization"],"prefix":"10.1038","volume":"17","author":[{"given":"Jianbo","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luxi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9947-418X","authenticated-orcid":false,"given":"Weitao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7217-0111","authenticated-orcid":false,"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7414-0123","authenticated-orcid":false,"given":"Hui","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"8732_CR1","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2020.12.007","volume":"32","author":"P Bossi","year":"2021","unstructured":"Bossi P, Chan AT, Licitra L, Trama A, Orlandi E, Hui EP, et al. Nasopharyngeal carcinoma: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2021;32:452\u201365.","journal-title":"Ann Oncol"},{"key":"8732_CR2","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/cac2.12218","volume":"41","author":"L-L Tang","year":"2021","unstructured":"Tang L-L, Chen Y-P, Chen C-B, Chen M-Y, Chen N-Y, Chen X-Z, et al. The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. Cancer Commun. 2021;41:1195\u2013227.","journal-title":"Cancer Commun"},{"key":"8732_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","volume":"18","author":"KCW Wong","year":"2021","unstructured":"Wong KCW, Hui EP, Lo K-W, Lam WKJ, Johnson D, Li L, et al. Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol. 2021;18:679\u201395.","journal-title":"Nat Rev Clin Oncol"},{"key":"8732_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/cac2.12159","volume":"41","author":"SS Poh","year":"2021","unstructured":"Poh SS, Soong YL, Sommat K, Lim CM, Fong KW, Tan TW, et al. Retreatment in locally recurrent nasopharyngeal carcinoma: current status and perspectives. Cancer Commun. 2021;41:361\u201370.","journal-title":"Cancer Commun"},{"key":"8732_CR5","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.ijrobp.2009.11.024","volume":"79","author":"WT Ng","year":"2011","unstructured":"Ng WT, Lee MCH, Hung WM, Choi CW, Lee KC, Chan OSH, et al. Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2011;79:420\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"8732_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-9-60","volume":"9","author":"F Kong","year":"2014","unstructured":"Kong F, Ying H, Du C, Huang S, Zhou J, Chen J, et al. Patterns of local-regional failure after primary intensity modulated radiotherapy for nasopharyngeal carcinoma. Radiat Oncol. 2014;9:60.","journal-title":"Radiat Oncol"},{"key":"8732_CR7","first-page":"203","volume":"75","author":"L-L Tang","year":"2025","unstructured":"Tang L-L, Chen L, Xu G-Q, Zhang N, Huang C-L, Li W-F, et al. Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: an open-label, noninferiority, multicenter, randomized phase 3 trial. CA Cancer J Clin. 2025;75:203\u201315.","journal-title":"CA Cancer J Clin"},{"key":"8732_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-023-02373-7","volume":"18","author":"X Zhou","year":"2023","unstructured":"Zhou X, Zhu J, Zhou C, Wang W, Ding W, Chen M, et al. Failure patterns of locoregional recurrence after reducing target volumes in patients with nasopharyngeal carcinoma receiving adaptive replanning during intensity-modulated radiotherapy: a single-center experience in China. Radiat Oncol. 2023;18:190.","journal-title":"Radiat Oncol"},{"key":"8732_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.tips.2017.11.003","volume":"39","author":"H Wang","year":"2018","unstructured":"Wang H, Mu X, He H, Zhang X-D. Cancer radiosensitizers. Trends Pharmacol Sci. 2018;39:24\u201348.","journal-title":"Trends Pharmacol Sci"},{"key":"8732_CR10","first-page":"23","volume":"12","author":"W Chen","year":"2015","unstructured":"Chen W, Hu G-H. Biomarkers for enhancing the radiosensitivity of nasopharyngeal carcinoma. Cancer Biol Med. 2015;12:23\u201332.","journal-title":"Cancer Biol Med"},{"key":"8732_CR11","doi-asserted-by":"publisher","first-page":"114126","DOI":"10.1016\/j.biopha.2022.114126","volume":"158","author":"S Sriramulu","year":"2023","unstructured":"Sriramulu S, Thoidingjam S, Brown SL, Siddiqui F, Movsas B, Nyati S. Molecular targets that sensitize cancer to radiation killing: from the bench to the bedside. Biomed Pharmacother. 2023;158:114126.","journal-title":"Biomed Pharmacother"},{"key":"8732_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13046-018-0758-7","volume":"37","author":"L Tang","year":"2018","unstructured":"Tang L, Wei F, Wu Y, He Y, Shi L, Xiong F, et al. Role of metabolism in cancer cell radioresistance and radiosensitization methods. J Exp Clin Cancer Res. 2018;37:87.","journal-title":"J Exp Clin Cancer Res"},{"key":"8732_CR13","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ccell.2024.03.011","volume":"42","author":"G Lei","year":"2024","unstructured":"Lei G, Zhuang L, Gan B. The roles of ferroptosis in cancer: tumor suppression, tumor microenvironment, and therapeutic interventions. Cancer Cell. 2024;42:513\u201334.","journal-title":"Cancer Cell"},{"key":"8732_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021;18:280\u201396.","journal-title":"Nat Rev Clin Oncol"},{"key":"8732_CR15","doi-asserted-by":"publisher","first-page":"144742","DOI":"10.1016\/j.ijbiomac.2025.144742","volume":"317","author":"W Li","year":"2025","unstructured":"Li W, Liang L, Liu S, Zeng F, Cao J, Lei Y, et al. CD38 inhibits ferroptosis to promote radiotherapy resistance in nasopharyngeal carcinoma by competitively binding to TRIM21 to stabilize SLC7A11 protein. Int J Biol Macromol. 2025;317:144742.","journal-title":"Int J Biol Macromol"},{"key":"8732_CR16","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41416-024-02574-1","volume":"130","author":"Y Chen","year":"2024","unstructured":"Chen Y, Feng Y, Lin Y, Zhou X, Wang L, Zhou Y, et al. GSTM3 enhances radiosensitivity of nasopharyngeal carcinoma by promoting radiation-induced ferroptosis through USP14\/FASN axis and GPX4. Br J Cancer. 2024;130:755\u201368.","journal-title":"Br J Cancer"},{"key":"8732_CR17","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1007\/s13238-021-00841-y","volume":"12","author":"G Lei","year":"2021","unstructured":"Lei G, Mao C, Yan Y, Zhuang L. Gan B. Ferroptosis, radiotherapy, and combination therapeutic strategies. Protein Cell. 2021;12:836\u201357.","journal-title":"Protein Cell"},{"key":"8732_CR18","doi-asserted-by":"publisher","first-page":"110686","DOI":"10.1016\/j.radonc.2024.110686","volume":"203","author":"X Huang","year":"2025","unstructured":"Huang X, Lin K, Chen W, Zhang D, Khan M, Ye X, et al. Modulation of the local angiotensin II: suppression of ferroptosis and radiosensitivity in nasopharyngeal carcinoma via the HIF-1\u03b1-HILPDA axis. Radiother Oncol. 2025;203:110686.","journal-title":"Radiother Oncol"},{"key":"8732_CR19","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.7150\/ijbs.100518","volume":"21","author":"Z Dai","year":"2025","unstructured":"Dai Z, Lin B, Qin M, Lin Y, Wang L, Liao K, et al. METTL3-mediated m6A modification of SLC7A11 enhances nasopharyngeal carcinoma radioresistance by inhibiting ferroptosis. Int J Biol Sci. 2025;21:1837\u201351.","journal-title":"Int J Biol Sci"},{"key":"8732_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07477-4","volume":"16","author":"P Zhou","year":"2025","unstructured":"Zhou P, Peng X, Zhang K, Cheng J, Tang M, Shen L, et al. HAT1\/HDAC2 mediated ACSL4 acetylation confers radiosensitivity by inducing ferroptosis in nasopharyngeal carcinoma. Cell Death Dis. 2025;16:160.","journal-title":"Cell Death Dis"},{"key":"8732_CR21","doi-asserted-by":"publisher","first-page":"31055","DOI":"10.1021\/acsnano.4c07676","volume":"18","author":"D Wang","year":"2024","unstructured":"Wang D, Tang L, Chen M, Gong Z, Fan C, Qu H, et al. Nanocarriers targeting circular RNA ADARB1 boost radiosensitivity of nasopharyngeal carcinoma through synergically promoting ferroptosis. ACS Nano. 2024;18:31055\u201375.","journal-title":"ACS Nano"},{"key":"8732_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41392-022-01038-3","volume":"7","author":"J Pan","year":"2022","unstructured":"Pan J, Zhou L, Zhang C, Xu Q, Sun Y. Targeting protein phosphatases for the treatment of inflammation-related diseases: from signaling to therapy. Signal Transduct Target Ther. 2022;7:177.","journal-title":"Signal Transduct Target Ther"},{"key":"8732_CR23","doi-asserted-by":"publisher","first-page":"3196\u2013.e17","DOI":"10.1016\/j.cell.2023.05.049","volume":"186","author":"H Li","year":"2023","unstructured":"Li H, Wang J, Kuan TA, Tang B, Feng L, Wang J, et al. Pathogen protein modularity enables elaborate mimicry of a host phosphatase. Cell. 2023;186:3196\u2013.e17.","journal-title":"Cell."},{"key":"8732_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41388-021-02068-x","volume":"41","author":"P Amin","year":"2022","unstructured":"Amin P, Awal S, Vigneron S, Roque S, Mechali F, Labb\u00e9 JC, et al. PP2A-B55: substrates and regulators in the control of cellular functions. Oncogene. 2022;41:1\u201314.","journal-title":"Oncogene."},{"key":"8732_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.biopha.2016.03.043","volume":"81","author":"D Bi","year":"2016","unstructured":"Bi D, Ning H, Liu S, Que X, Ding K. miR-1301 promotes prostate cancer proliferation through directly targeting PPP2R2C. Biomed Pharmacother. 2016;81:25\u201330.","journal-title":"Biomed Pharmacother"},{"key":"8732_CR26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.biopha.2015.12.005","volume":"77","author":"A-H Wu","year":"2016","unstructured":"Wu A-H, Huang Y, Zhang L-Z, Tian G, Liao Q-Z, Chen S-L. MiR-572 prompted cell proliferation of human ovarian cancer cells by suppressing PPP2R2C expression. Biomed Pharmacother. 2016;77:92\u201397.","journal-title":"Biomed Pharmacother"},{"key":"8732_CR27","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1016\/j.febslet.2013.09.029","volume":"587","author":"Y-L Fan","year":"2013","unstructured":"Fan Y-L, Chen L, Wang J, Yao Q, Wan J-Q. Over expression of PPP2R2C inhibits human glioma cells growth through the suppression of mTOR pathway. FEBS Lett. 2013;587:3892\u20137.","journal-title":"FEBS Lett"},{"key":"8732_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-015-0164-6","volume":"15","author":"Y-N Li","year":"2015","unstructured":"Li Y-N, Cao Y-Q, Wu X, Han G-S, Wang L-X, Zhang Y-H, et al. The association between Salt-inducible kinase 2 (SIK2) and gamma isoform of the regulatory subunit B55 of PP2A (B55gamma) contributes to the survival of glioma cells under glucose depletion through inhibiting the phosphorylation of S6K. Cancer Cell Int. 2015;15:21.","journal-title":"Cancer Cell Int"},{"key":"8732_CR29","doi-asserted-by":"publisher","first-page":"e13780","DOI":"10.1111\/acel.13780","volume":"22","author":"J Xing","year":"2023","unstructured":"Xing J, Chen K, Gao S, Pousse M, Ying Y, Wang B, et al. Protein phosphatase 2A activators reverse age-related behavioral changes by targeting neural cell senescence. Aging Cell. 2023;22:e13780.","journal-title":"Aging Cell"},{"key":"8732_CR30","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1038\/onc.2010.569","volume":"30","author":"X Xiong","year":"2011","unstructured":"Xiong X, Zhao Y, He H, Sun Y. Ribosomal protein S27-like and S27 interplay with p53-MDM2 axis as a target, a substrate and a regulator. Oncogene. 2011;30:1798\u2013811.","journal-title":"Oncogene."},{"key":"8732_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-020-03082-9","volume":"11","author":"S Sun","year":"2020","unstructured":"Sun S, He H, Ma Y, Xu J, Chen G, Sun Y, et al. Inactivation of ribosomal protein S27-like impairs DNA interstrand cross-link repair by destabilization of FANCD2 and FANCI. Cell Death Dis. 2020;11:1\u201310.","journal-title":"Cell Death Dis"},{"key":"8732_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0192-3","volume":"9","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Tan M, Liu X, Xiong X, Sun Y. Inactivation of ribosomal protein S27-like confers radiosensitivity via the Mdm2-p53 and Mdm2-MRN-ATM axes. Cell Death Dis. 2018;9:145.","journal-title":"Cell Death Dis"},{"key":"8732_CR33","doi-asserted-by":"publisher","first-page":"13419","DOI":"10.1096\/fj.202000530RRR","volume":"34","author":"X Xiong","year":"2020","unstructured":"Xiong X, Cui D, Bi Y, Sun Y, Zhao Y. Neddylation modification of ribosomal protein RPS27L or RPS27 by MDM2 or NEDP1 regulates cancer cell survival. FASEB J. 2020;34:13419\u201329.","journal-title":"FASEB J"},{"key":"8732_CR34","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1111\/cas.16168","volume":"115","author":"Q Yang","year":"2024","unstructured":"Yang Q, Zhou X, Fang J, Lin A, Zhang H, Cheng Q, et al. Development and validation of a radiosensitivity model to evaluate radiotherapy benefits in pan-cancer. Cancer Sci. 2024;115:1820\u201333.","journal-title":"Cancer Sci"},{"key":"8732_CR35","doi-asserted-by":"publisher","first-page":"eabh2445","DOI":"10.1126\/sciadv.abh2445","volume":"8","author":"JK Tay","year":"2022","unstructured":"Tay JK, Zhu C, Shin JH, Zhu SX, Varma S, Foley JW, et al. The microdissected gene expression landscape of nasopharyngeal cancer reveals vulnerabilities in FGF and noncanonical NF-\u03baB signaling. Sci Adv. 2022;8:eabh2445.","journal-title":"Sci Adv"},{"key":"8732_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56134-z","volume":"16","author":"R Zhang","year":"2025","unstructured":"Zhang R, Shen Y, Zhou X, Li J, Zhao H, Zhang Z, et al. Hypoxia-tropic delivery of nanozymes targeting transferrin receptor 1 for nasopharyngeal carcinoma radiotherapy sensitization. Nat Commun. 2025;16:890.","journal-title":"Nat Commun"},{"key":"8732_CR37","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0140-6736(21)00233-6","volume":"398","author":"RA Chandra","year":"2021","unstructured":"Chandra RA, Keane FK, Voncken FEM, Thomas CR. Contemporary radiotherapy: present and future. Lancet. 2021;398:171\u201384.","journal-title":"Lancet."},{"key":"8732_CR38","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/febs.13573","volume":"283","author":"J Sangodkar","year":"2016","unstructured":"Sangodkar J, Farrington CC, McClinch K, Galsky MD, Kastrinsky DB, Narla G. All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase. FEBS J. 2016;283:1004\u201324.","journal-title":"FEBS J"},{"key":"8732_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.canlet.2013.02.036","volume":"335","author":"P Seshacharyulu","year":"2013","unstructured":"Seshacharyulu P, Pandey P, Datta K, Batra SK. Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett. 2013;335:9\u201318.","journal-title":"Cancer Lett"},{"key":"8732_CR40","doi-asserted-by":"publisher","first-page":"101105","DOI":"10.1016\/j.redox.2019.101105","volume":"27","author":"D Raman","year":"2019","unstructured":"Raman D, Pervaiz S. Redox inhibition of protein phosphatase PP2A: Potential implications in oncogenesis and its progression. Redox Biol. 2019;27:101105.","journal-title":"Redox Biol"},{"key":"8732_CR41","doi-asserted-by":"publisher","first-page":"eabe2967","DOI":"10.1126\/scitranslmed.abe2967","volume":"13","author":"JP Vainonen","year":"2021","unstructured":"Vainonen JP, Momeny M, Westermarck J. Druggable cancer phosphatases. Sci Transl Med. 2021;13:eabe2967.","journal-title":"Sci Transl Med"},{"key":"8732_CR42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/nature05351","volume":"445","author":"US Cho","year":"2007","unstructured":"Cho US, Xu W. Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme. Nature. 2007;445:53\u201357.","journal-title":"Nature."},{"key":"8732_CR43","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1128\/MCB.01730-12","volume":"33","author":"V Kolupaeva","year":"2013","unstructured":"Kolupaeva V, Daempfling L, Basilico C. The B55\u03b1 regulatory subunit of protein phosphatase 2A mediates fibroblast growth factor-induced p107 dephosphorylation and growth arrest in chondrocytes. Mol Cell Biol. 2013;33:2865\u201378.","journal-title":"Mol Cell Biol"},{"key":"8732_CR44","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.molcel.2016.06.024","volume":"63","author":"EPT Hertz","year":"2016","unstructured":"Hertz EPT, Kruse T, Davey NE, L\u00f3pez-M\u00e9ndez B, Sigur\u00f0sson JO, Montoya G, et al. A conserved motif provides binding specificity to the PP2A-B56 phosphatase. Mol Cell. 2016;63:686\u201395.","journal-title":"Mol Cell"},{"key":"8732_CR45","doi-asserted-by":"publisher","first-page":"16104","DOI":"10.1074\/jbc.M710313200","volume":"283","author":"AJ Davis","year":"2008","unstructured":"Davis AJ, Yan Z, Martinez B, Mumby MC. Protein phosphatase 2A is targeted to cell division control protein 6 by a calcium-binding regulatory subunit. J Biol Chem. 2008;283:16104\u201314.","journal-title":"J Biol Chem"},{"key":"8732_CR46","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.1074\/jbc.275.8.5257","volume":"275","author":"CS Moreno","year":"2000","unstructured":"Moreno CS, Park S, Nelson K, Ashby D, Hubalek F, Lane WS, et al. WD40 repeat proteins striatin and S\/G(2) nuclear autoantigen are members of a novel family of calmodulin-binding proteins that associate with protein phosphatase 2A. J Biol Chem. 2000;275:5257\u201363.","journal-title":"J Biol Chem"},{"key":"8732_CR47","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1042\/CS20201367","volume":"135","author":"DL Brautigan","year":"2021","unstructured":"Brautigan DL, Farrington C, Narla G. Targeting protein phosphatase PP2A for cancer therapy: development of allosteric pharmaceutical agents. Clin Sci (Lond). 2021;135:1545\u201356.","journal-title":"Clin Sci (Lond)"},{"key":"8732_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04425-z","volume":"9","author":"WS Ho","year":"2018","unstructured":"Ho WS, Wang H, Maggio D, Kovach JS, Zhang Q, Song Q, et al. Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade. Nat Commun. 2018;9:2126.","journal-title":"Nat Commun"},{"key":"8732_CR49","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11060-020-03517-5","volume":"148","author":"D Maggio","year":"2020","unstructured":"Maggio D, Ho WS, Breese R, Walbridge S, Wang H, Cui J, et al. Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma. J Neurooncol. 2020;148:231\u201344.","journal-title":"J Neurooncol"},{"key":"8732_CR50","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1158\/0008-5472.CAN-22-3382","volume":"83","author":"I Mondal","year":"2023","unstructured":"Mondal I, Das O, Sun R, Gao J, Yu B, Diaz A, et al. PP2Ac deficiency enhances tumor immunogenicity by activating STING-Type I interferon signaling in glioblastoma. Cancer Res. 2023;83:2527\u201342.","journal-title":"Cancer Res"},{"key":"8732_CR51","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.canlet.2017.11.035","volume":"415","author":"WS Ho","year":"2018","unstructured":"Ho WS, Sizdahkhani S, Hao S, Song H, Seldomridge A, Tandle A, et al. LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation. Cancer Lett. 2018;415:217\u201326.","journal-title":"Cancer Lett"},{"key":"8732_CR52","doi-asserted-by":"publisher","first-page":"108834","DOI":"10.1016\/j.pharmthera.2025.108834","volume":"269","author":"DA Neale","year":"2025","unstructured":"Neale DA, Morris JC, Verrills NM, Ammit AJ. Understanding the regulatory landscape of protein phosphatase 2A (PP2A): pharmacological modulators and potential therapeutics. Pharmacol Ther. 2025;269:108834.","journal-title":"Pharmacol Ther."},{"key":"8732_CR53","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-023-01462-z","volume":"8","author":"S Guo","year":"2023","unstructured":"Guo S, Yao Y, Tang Y, Xin Z, Wu D, Ni C, et al. Radiation-induced tumor immune microenvironments and potential targets for combination therapy. Signal Transduct Target Ther. 2023;8:205.","journal-title":"Signal Transduct Target Ther"},{"key":"8732_CR54","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41420-023-01645-1","volume":"9","author":"X Chen","year":"2023","unstructured":"Chen X, Zhang L, He Y, Huang S, Chen S, Zhao W, et al. Regulation of m6A modification on ferroptosis and its potential significance in radiosensitization. Cell Death Discov. 2023;9:343.","journal-title":"Cell Death Discov"},{"key":"8732_CR55","doi-asserted-by":"publisher","first-page":"103964","DOI":"10.1016\/j.critrevonc.2023.103964","volume":"185","author":"J Lee","year":"2023","unstructured":"Lee J, Roh J-L. Epithelial-mesenchymal plasticity: implications for ferroptosis vulnerability and cancer therapy. Crit Rev Oncol Hematol. 2023;185:103964.","journal-title":"Crit Rev Oncol Hematol"},{"key":"8732_CR56","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Meng Y, Li D, Yao L, Le J, Liu Y, et al. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Signal Transduct Target Ther. 2024;9:55.","journal-title":"Signal Transduct Target Ther"},{"key":"8732_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07541-z","volume":"16","author":"M Huang","year":"2025","unstructured":"Huang M, Wu Y, Wei X, Cheng L, Fu L, Yan H, et al. Trifluridine\/tipiracil induces ferroptosis by targeting p53 via the p53-SLC7A11 axis in colorectal cancer 3D organoids. Cell Death Dis. 2025;16:255.","journal-title":"Cell Death Dis"},{"key":"8732_CR58","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1101\/gad.334219.119","volume":"34","author":"D Venkatesh","year":"2020","unstructured":"Venkatesh D, O\u2019Brien NA, Zandkarimi F, Tong DR, Stokes ME, Dunn DE, et al. MDM2 and MDMX promote ferroptosis by PPAR\u03b1-mediated lipid remodeling. Genes Dev. 2020;34:526\u201343.","journal-title":"Genes Dev"},{"key":"8732_CR59","doi-asserted-by":"publisher","first-page":"103362","DOI":"10.1016\/j.redox.2024.103362","volume":"77","author":"Z Xin","year":"2024","unstructured":"Xin Z, Hu C, Zhang C, Liu M, Li J, Sun X, et al. LncRNA-HMG incites colorectal cancer cells to chemoresistance via repressing p53-mediated ferroptosis. Redox Biol. 2024;77:103362.","journal-title":"Redox Biol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08732-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08732-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08732-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T10:03:31Z","timestamp":1781863411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08732-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8732"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08732-y","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Animal experiments were conducted according to the protocols approved by the ethics committee of the Zhujiang Hospital of Southern Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"587"}}